TaiGen Biotechnology Co., Ltd. announced today that in a phase 1 study in healthy volunteers TG-0054, a chemokine receptor CXCR4 antagonist, was well tolerated and rapidly mobilized stem cells and endothelial progenitor cells from bone marrow into peripheral blood. The number of CD34+ stem cells in circulation after one dose of TG-0054 was equal or higher than reported cell numbers needed for stem cell transplantation in cancer patients. The observed AEs were all mild and transient. A phase 2 study in stem cell transplantation for multiple myeloma, non-Hodgkin lymphoma and Hodgkin disease patients is currently being initiated (…)
A new treatment regimen can help some patients who have blood cancer to live disease-free longer, University of Floridaresearchers and colleagues have found.
Low doses of a drug called lenalidomide can help hold off the return of multiple myeloma after bone marrow transplantation. Patients who took the drug to maintain health also lived longer than those who did not take the drug.
“In choosing maintenance therapy we look at a few things,” said study co-author Dr. Jan S. Moreb, clinical director of hematologic malignancies in the UF College of Medicine’s division of hematology/oncology and a member of the UF Shands Cancer
Image via Wikipedia
Taming the bad cancer stem cells, genetically modifying them to arm them against disease and cancer-from defusing the bomb. Bet on cell girls ‘GM’, transformed into cancer killer bullets, one of five projects funded by AIRC (Italian Association for Cancer Research) with 60 million in five years thanks to the funds of 5 per thousand.
Studies of molecular oncology clinic, chosen by a jury of 18 super-foreign experts, who share one big final goal: to train a new generation of physicians, researchers are able to bridge the gap between the lab bench and the bedside. In five years’
A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system.
Outlined in the British Journal of Hematology, the Phase II clinical trial was led by Amir Toor, M.D., hematologist-oncologist in the Bone Marrow Transplant Program and research member of the Developmental Therapeutics program at VCU Massey Cancer Center. The multi-phased therapy first treats patients with a combination of the drugs azacitidine and lenalidomide. Azacitidine
A team of doctors of haematology department of Nilratan Sircar Medical College and Hospital performed a blood stem cell transplantation on a patient wherein they successfully re-infused blood stem cells into a patient’s bloodstream on 30 January. The patient is suffering from a type of blood cancer known as multiple myeloma.
Mrs Bela Samanta, a resident of Burdwan, has been a patient of leukaemia for past one year. On 16 December she was admitted to the hospital in a critical condition. Doctors examined her and said there was a need for this transplantation, if the patient wanted to lead a